15
Micromesh stent technology – also a solution for peripheral arteries? Dr Daniel Périard Angiology Hôpital Cantonal Fribourg Switzerland

Micromesh stent technology also a solution for peripheral ... · (3) A novel carotid stent for sustained embolic protection, Subbarao Myla, Newport Beach, USA, Presentation CIRSE

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

  • Micromesh stent technology – also a solution for peripheral

    arteries?

    Dr Daniel Périard Angiology

    Hôpital Cantonal Fribourg

    Switzerland

  • Disclosure

    I have no potential conflict of interest regarding this

    presentation.

  • RoadSaver ™ carotid stent

    It is a double layer of braided nitinol wires

    The outer layer provides high radial force, flexibility and conformation to tortuous anatomy

    The inner micromesh layer has the smallest cell size, preventing plaque protrusion and embolism

    5Fr rapid exchange platform

    Fully re-sheathable and repositionable

  • (1) Am J Cardiol. 2015 Sep 15;116(6):977-81. doi: 10.1016/j.amjcard.2015.05.063. Epub 2015 Jun 25. (2) Tailored carotid artery stenting, Pieniazek et al., J. Endovasc. Ther. (3) A novel carotid stent for sustained embolic protection, Subbarao Myla, Newport Beach, USA, Presentation CIRSE 14.-18.September 2013, Barcelona, Spain (4) Safety of Slender 5Fr Transradial Approach for Carotid Artery Stenting With a Novel Nitinol Double-Layer Micromesh Stent. Kedev S., et al., Am J Cardiol. 2015 Sep 15;116(6):977-81. doi: 10.1016/j.amjcard.2015.05.063. Epub 2015 Jun 25. (5) Initial clinical experience with the micromesh roadsaver carotid artery stent for the treatment of patients with symptomatic carotid artery disease. Hopf-Jensen S, et al., J Endovasc Ther. 2015 Apr;22(2):220-5. doi: 10.1177/1526602815576337. (6) Cremonesi A et al. Carotid Artery Stenting an update EHJ2015 (7) Deloose, K. et al.,Clinical Evidence for Roadsaver Carotid Stent the CLEAR-ROAD trial, CIRSE 2014 (8) Amor, M. et al. Pre-Clinical and first clinical experiences with the Micromesh Carotid stent Roadsaver, LINC 2014

    Italian Registry 3 Centers:

    Cremonesi/ Castriota (Cotignola) Setacci/ Cappelli (Siena) Rabbia/ Ruffino (Turin)

    > 150 Patients enroled Results

    No complications No plaque prolapse Fewer and smaller new white lesions compared to C-Guard, diagnosed by DW-MRI

    Clearroad Trial 9 Centers

    Peeters (Bonheiden), Bosiers/ Deloose (Dendermonde), Maene (Aalst), Setacci/ Cappelli (Siena), Langhoff (Berlin), Müller-Hülsbeck (Flensburg), Sievert (Frankfurt), Scheinert/ Schmidt (Leipzig), Torsello/ Schwindt (Münster)

    81 patients enroled

    Results (preliminary)

    No stroke

    1 MI

    Ongoing studies evaluating the Roadsaver ™ for CAS

  • open cell laser-cut nitinol stent may

    be unable to achieve a good lumen

    patency and lack of resistance to

    high external compression

    result after multiple in-

    stent angioplasties

    RoadSaver ™

  • The Roadsaver ™ micromesh stent for SFA/popliteal extremely calcified lesions:

    a pilot study Monocentric study

    Investigator initiated

    Inclusion criteria:

    • PAD with severely calcified SFA/pop lesions

    • At least one run off vessel before Roadsaver ™ implantation

    Objectives: technical aspects

    success of implantation

    security of the Roadsaver ™

    efficacy of the Roadsaver ™

    Follow-up: clinical examination and duplex scan 1, 6, 12, 18, 24 M

  • The Roadsaver ™ micromesh stent for SFA/popliteal extremely calcified lesions

    Inclusion current status (started May 2015) :

    baseline characteristics patients n=21

    age (y) 75 ± 11

    gender (male) 67%

    diabetes 38%

    hypertension 81%

    smoking (past or current) 43%

    hyperlipidemia 62%

    renal failure (ClCr ≤ 30 ml/min) 14%

    Rutherford 3 or 4 52%

    5 9.5%

    6 14%

  • The Roadsaver ™ micromesh stent for SFA/popliteal extremely calcified lesions

    Lesions characteristics:

    patients n=21

    SFA 71%

    poplitea 67%

    calcifications mild 33%

    heavy (>180°) 6 (30 %)

    massive (360°) 33%29%

    mean degree of stenosis 89±11 %

    occlusions 48%

    sub-intimal recanalisation 14%

    treated lesion lenght (PTA) (mm) 169±129 mm

    stented segment lenght (mm) 35±9 mm

    debulking 19%

  • patients n=21 procedure primary success

    100 %

    30 days primary patency 100%

    30 days freedom from TLR 100%

    30 days freedom from TVR 96% *

    patients n=15

    6 months primary patency 100 %

    6 months in stent restenosis (PSV≥2) 0 %

    * recanalisation of a lesion proximal to the Roadsaver

    The Roadsaver ™ micromesh stent for SFA/popliteal extremely calcified lesions

    Results:

  • Immediate result of

    the Roadsaver™

    implantation no restenosis at 6 months Duplex

    84 y woman, rutherford 4

  • The Roadsaver ™ may be used as a flow diverter for small poplitea aneurysm. High plaque coverage operates as a metallic covered stent, but keeps the side branch open

    Popliteal calcified

    stenosis with post-

    stenotic small

    aneurysm

    Roadsaver™ used

    as a scaffold for

    the stenosis and

    flow diverter for

    the aneurysm

    Thrombosis of the

    aneurysm and

    preserved flow in

    the stent and the

    side branch

    day 0 day 18

    76 y man, rutherford 3

  • conclusions

    Innovative dual layer stent with excellent scaffold for SFA/pop calcified lesions.

    Safe

    Ease of use

    Absence of restenosis at 6 months

    Candidate for popliteal aneurysm cure (flow diverter)

    Further studies must confirm these results

  • Micromesh stent technology – also a solution for peripheral

    arteries?

    Dr Daniel Périard Angiology

    Hôpital Cantonal Fribourg

    Switzerland